PCSK9 inhibitors × lipids

Observational studyCardiovascular drugs and therapy2026

Real-World Efficacy of Inclisiran in Veneto Region (Italy): The INCLIVEN Multicenter Registry.

Francesco Briani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Two numbers in the abstract

the abstract, start to end

significantly fell to 56.7 ± 40.4 mg/dl (-52.3 ± 24.3%; p < 0.001) at 3 months (n = 238) and to 60.5 ± 40.1 mg/dl (-50.0 ± 22.7%; p < 0.001) at 9 months

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
LDL-C concentrationinclisiran vs baseline
−52.3
LDL-C concentrationinclisiran vs baseline
−50.0
PCSK9 inhibitorsLipids
1 / 3

4 papers cite it

2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 40663298